Recent content by PennState-JD

If there are larger trials with death rates for the placebo arm established, why wouldn’t those be allowed by the FDA?  I get that the methodology would add a variable of the timing being different, but wouldn’t it be better to have a much more reliable placebo death rate based on a sample size...

Could be good opportunity to buy AXON on the dip. 

Same boat here.  Nice little pop today. 

Up 28% today... nice.  Still only $.0363.  What is your exit plan on this @NajehHejan? 

Trimmed today to lock in some gains (bought at 1.29) and have 10k remaining at cost of 2.89.     @chet thank you for the tip here that just paid a year in tuition.  

This has been a solid position for me over the past couple years.  High growth and margins in the data side of the business, and long term contracts.  With more of a push around transparency and also moving into other government agencies, I believe this continues to grow on a healthy basis. Plus...

Big thanks to whomever mentioned CLSK right before Xmas.  Up 30% today and a double since 12/21. 

@Todem really appreciate your tips earlier this year. Tailed you on several of your dividend picks and also the volatility plays.  Quick question on BLDP — what is their leg up versus FCEL?  Curious how you see the two compared to each other. 

Maybe investors hangout should focus their emails on the MyPillow guy or even the TrumpyBear inventor.  

There will be interest IF there is positive news from the FDA or Nasdaq.  The “news” coming from NP is falling on deaf ears and it is basically a day trading stock that the shorts can manipulate in the absence of real 3rd party developments.  FDA approval would generate a revenue stream which...

Was thinking the same as djmich one why messing around with a smaller sample, but I think they are limiting it to patients with a higher score (4+) to ensure the results come back the same as what they saw in Phase 2.  If the phase two results were p = .02, then odds are 98% it did not occur by...

There are all kinds of media pieces, tweets etc. pointing out the gambling that is going on with millennials reviewing government money.  This isn’t exactly new except it ties in CYDY.  Look at the back and forth with Portnoy and Kramer, and the down with the suits schtick.  We’ve even discussed...

I think the SP will continue to float where it is now, and will jump on this news depending on which endpoint is statistically significant.  If they can demonstrate a reduction in mortality, I think that is best case because that would be the indicator that should be easiest to monetize and get...

Couple thoughts from the latest interview: - he said statistically significant parameter, not parameters.  Thinking there is one here and the supporting endpoints are directionally good, but perhaps not at a p value for statistical significance. - said they were at 175 enrolled patients and I...

Read an article today that quoted Fauci speaking about vaccines.  Said the vaccine had to be safe and ideally reduce the rate 50%.  Said 60+% would be better.  Does this way of thinking also carry over to therapeutics?